ENTX (Entera Bio) Risk Assessment

View and export this data going back to 2018. Start your Free Trial

What is Entera Bio Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Entera Bio is: No Data: Cannot be evaluated.

Competitive Comparison of Entera Bio's Risk Assessment

For the Biotechnology subindustry, Entera Bio's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entera Bio's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Entera Bio's Risk Assessment falls into.

Entera Bio (NAS:ENTX) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Entera Bio Risk Assessment Related Terms

Thank you for viewing the detailed overview of Entera Bio's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Entera Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (NAS:ENTX) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

5DT:Germany

Address

Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002

Website

https://www.enterabio.com

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Executives

Haya Taitel	director	KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM L3 9112002
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Gerald M Lieberman	director	C/O ALLIANCE CAPITAL, 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Sean Ellis	director	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Dana Yaacov-garbeli	officer: Israel CFO	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Phillip Schwartz	director, officer: President of R&D	C/O ENTERA BIO LTD., KIRYAT HADASSAH, MINRAV BUILDING, 5TH FL, JERUSALEM L3 9112002
Ramesh Ratan	officer: U.S.based CFO	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Ron Mayron	director	22A ORANIM ST, HOD HASHARON L3 4526333
Spiros Jamas	director, officer: Chief Executive Officer
Gerald M Ostrov	director	41 WATERVIEW, LONG BRANCH NJ 07740
Yonatan Malca	director	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Roger Garceau	director	550 HILLS DRIVE, BEDMINSTER NJ 07921
Hillel Galitzer	officer: Chief Operating Officer	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Santora Arthur C Ii	officer: Chief Medical Officer	KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002